Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Research with premature infant livers touches a nerve

Lola Reid (inset) says infant livers are a superior source of stem cells. Credit: Courtesy: Nicholas Moss

Most stem cell researchers are accustomed to their work being greeted with controversy. But Lola Reid's work is so contentious even those in the field call her a scientific maverick.

Reid, a researcher at the University of North Carolina, is trying to isolate stem cells from the livers of premature infants who have died. The university was wary about her proposal, but after five years of meetings and reviews, in 2002, it granted her permission to proceed.

Reid says infant livers contain a higher concentration of fast-growing progenitor cells than adult livers. But her data are as yet unpublished and she is just moving into animal studies.

Many scientists are skeptical of Reid's work, but those interviewed for this story did not wish to be identified. Reid says it is only natural that the scientists are cautious. “They can wait until we publish all this,” she says. “I'm just trying to give them a heads-up that this is a new direction to go in.”

Reid's program is the first of its kind in the US. Premature babies are generally too small and underdeveloped to qualify as either donors or recipients of organs. Not surprisingly, Reid and her colleagues have found that the project is fraught with challenges and ethical dilemmas.

In some cases, families must be approached for the organs only hours after the mother has given birth and many devastated parents decline. The researchers enlisted the help of a local agency that asks families for adult organs.

The university's bioethicists helped word the consent form to specify that the organs would be used for research, and not for transplantation or therapy. The document also informs donors that the liver cells might benefit Vesta Therapeutics, a company Reid helped create to develop stem cell–based liver treatments.

During the past two years, Reid has collected about 12 neonate livers and says her team has been able to harvest cells from the livers seven to eight hours after death. She says the organs are thick with hepatic progenitor cells and the cells grow more rapidly than those harvested from adult livers.

One prominent stem cell researcher, who asked not to be named, says it is too early to predict whether the cells will offer any advantage over adult cells. Another says it is unclear whether Reid's findings will hold up when she moves into in vivo tests. But some researchers are cautiously optimistic that she might be on to something.

“It is clearly true that the therapeutic use of these cells is completely unknown at this time,” says Marcus Grompe, a hepatic stem cell researcher at Oregon Health & Science University. “But their proliferative capacity and the fact that they survive so long after death make them very interesting candidates,” he says. Grompe says he supports the science behind Reid's work, but “the emphasis should be on science, not application.”

It is clearly true that the therapeutic use of these cells is completely unknown at this time. Marcus Grompe, Oregon Health & Science University

Author information

Authors and Affiliations

Authors

Related links

Related links

Related external links

Lola Reid

Vesta Therapeutics

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ready, T. Research with premature infant livers touches a nerve. Nat Med 10, 762 (2004). https://doi.org/10.1038/nm0804-762a

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0804-762a

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing